Literature DB >> 9665983

Campylobacter species and Guillain-Barré syndrome.

I Nachamkin1, B M Allos, T Ho.   

Abstract

Since the eradication of polio in most parts of the world, Guillain-Barré syndrome (GBS) has become the most common cause of acute flaccid paralysis. GBS is an autoimmune disorder of the peripheral nervous system characterized by weakness, usually symmetrical, evolving over a period of several days or more. Since laboratories began to isolate Campylobacter species from stool specimens some 20 years ago, there have been many reports of GBS following Campylobacter infection. Only during the past few years has strong evidence supporting this association developed. Campylobacter infection is now known as the single most identifiable antecedent infection associated with the development of GBS. Campylobacter is thought to cause this autoimmune disease through a mechanism called molecular mimicry, whereby Campylobacter contains ganglioside-like epitopes in the lipopolysaccharide moiety that elicit autoantibodies reacting with peripheral nerve targets. Campylobacter is associated with several pathologic forms of GBS, including the demyelinating (acute inflammatory demyelinating polyneuropathy) and axonal (acute motor axonal neuropathy) forms. Different strains of Campylobacter as well as host factors likely play an important role in determining who develops GBS as well as the nerve targets for the host immune attack of peripheral nerves. The purpose of this review is to summarize our current knowledge about the clinical, epidemiological, pathogenetic, and laboratory aspects of campylobacter-associated GBS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665983      PMCID: PMC88896          DOI: 10.1128/CMR.11.3.555

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  167 in total

1.  Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome.

Authors:  A Chiba; S Kusunoki; T Shimizu; I Kanazawa
Journal:  Ann Neurol       Date:  1992-06       Impact factor: 10.422

2.  The Guillain-Barré syndrome following Campylobacter enteritis with recovery after plasmapheresis.

Authors:  O C Constant; C C Bentley; A M Denman; J R Lehane; H E Larson
Journal:  J Infect       Date:  1983-01       Impact factor: 6.072

3.  Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains.

Authors:  A J Lastovica; E A Goddard; A C Argent
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

4.  An acute axonal form of Guillain-Barré polyneuropathy.

Authors:  T E Feasby; J J Gilbert; W F Brown; C F Bolton; A F Hahn; W F Koopman; D W Zochodne
Journal:  Brain       Date:  1986-12       Impact factor: 13.501

5.  Guillain-Barré syndrome: epidemiology of an outbreak.

Authors:  S A Khoury
Journal:  Am J Epidemiol       Date:  1978-05       Impact factor: 4.897

6.  Human serum antibody response to Campylobacter jejuni infection as measured in an enzyme-linked immunosorbent assay.

Authors:  M J Blaser; D J Duncan
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

7.  Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice.

Authors:  B Buchwald; A Weishaupt; K V Toyka; J Dudel
Journal:  Neurosci Lett       Date:  1995-12-08       Impact factor: 3.046

8.  Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.

Authors:  H J Willison; J Veitch; G Paterson; P G Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

9.  Prognosis in severe Guillain-Barré syndrome.

Authors:  G F Cole; D J Matthew
Journal:  Arch Dis Child       Date:  1987-03       Impact factor: 3.791

10.  Identification of Gal(beta 1-3)GalNAc bearing glycoproteins at the nodes of Ranvier in peripheral nerve.

Authors:  S Apostolski; S A Sadiq; A Hays; M Corbo; L Suturkova-Milosevic; P Chaliff; K Stefansson; R G LeBaron; E Ruoslahti; A P Hays
Journal:  J Neurosci Res       Date:  1994-06-01       Impact factor: 4.164

View more
  171 in total

1.  Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain-Barré syndrome.

Authors:  T M Wassenaar; B N Fry; A J Lastovica; J A Wagenaar; P J Coloe; B Duim
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

3.  Identification of Campylobacter heat-stable and heat-labile antigens by combining the Penner and Lior serotyping schemes.

Authors:  David L Woodward; Frank G Rodgers
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Evaluation of methods for subtyping Campylobacter jejuni during an outbreak involving a food handler.

Authors:  C Fitzgerald; L O Helsel; M A Nicholson; S J Olsen; D L Swerdlow; R Flahart; J Sexton; P I Fields
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Evaluation of the Alexon-trend ProSpecT Campylobacter microplate assay.

Authors:  R Tolcin; M M LaSalvia; B A Kirkley; E A Vetter; F R Cockerill; G W Procop
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.

Authors:  H P Endtz; C W Ang; N van Den Braak; B Duim; A Rigter; L J Price; D L Woodward; F G Rodgers; W M Johnson; J A Wagenaar; B C Jacobs; H A Verbrugh; A van Belkum
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

7.  Development and Evaluation of CmeC Subunit Vaccine against Campylobacter jejuni.

Authors:  Ximin Zeng; Fuzhou Xu; Jun Lin
Journal:  J Vaccines Vaccin       Date:  2010-01-01

8.  Prevalence, development, and molecular mechanisms of bacteriocin resistance in Campylobacter.

Authors:  Ky Van Hoang; Norman J Stern; Arnold M Saxton; Fuzhou Xu; Ximin Zeng; Jun Lin
Journal:  Appl Environ Microbiol       Date:  2011-01-28       Impact factor: 4.792

9.  Expression, purification, crystallization and preliminary X-ray analysis of wild-type and of an active-site mutant of glyceraldehyde-3-phosphate dehydrogenase from Campylobacter jejuni.

Authors:  David S Tourigny; Paul R Elliott; Louise J Edgell; Gregg M Hudson; Peter C E Moody
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-12-22

10.  Heat Shock-Enhanced Conjugation Efficiency in Standard Campylobacter jejuni Strains.

Authors:  Ximin Zeng; Devarshi Ardeshna; Jun Lin
Journal:  Appl Environ Microbiol       Date:  2015-04-24       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.